Inozyme Pharma Past Earnings Performance
Past criteria checks 0/6
Inozyme Pharma's earnings have been declining at an average annual rate of -19.6%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-19.6%
Earnings growth rate
63.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -116.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?
Aug 03
Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion
Jul 30Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?
Apr 11Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward
Mar 08Inozyme Pharma GAAP EPS of -$0.38
Aug 15Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency
Jul 19Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?
Jul 12We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
Apr 06Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation
Dec 22Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth
Sep 08We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
May 22Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency
May 07We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely
Feb 06
Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder
Jan 04Inozyme Pharma (INZY) Investor Presentation - Slideshow
Dec 03Inozyme Pharma EPS misses by $1.02
Nov 12Revenue & Expenses Breakdown
How Inozyme Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -96 | 21 | 78 |
| 30 Jun 24 | 0 | -89 | 21 | 72 |
| 31 Mar 24 | 0 | -77 | 21 | 62 |
| 31 Dec 23 | 0 | -71 | 21 | 55 |
| 30 Sep 23 | 0 | -68 | 22 | 51 |
| 30 Jun 23 | 0 | -68 | 22 | 50 |
| 31 Mar 23 | 0 | -68 | 21 | 48 |
| 31 Dec 22 | 0 | -67 | 21 | 48 |
| 30 Sep 22 | 0 | -67 | 21 | 47 |
| 30 Jun 22 | 0 | -65 | 21 | 44 |
| 31 Mar 22 | 0 | -62 | 20 | 42 |
| 31 Dec 21 | 0 | -57 | 20 | 37 |
| 30 Sep 21 | 0 | -49 | 19 | 31 |
| 30 Jun 21 | 0 | -63 | 17 | 46 |
| 31 Mar 21 | 0 | -60 | 14 | 46 |
| 31 Dec 20 | 0 | -56 | 11 | 46 |
| 30 Sep 20 | 0 | -52 | 8 | 44 |
| 30 Jun 20 | 0 | -28 | 6 | 23 |
| 31 Mar 20 | 0 | -22 | 5 | 18 |
| 31 Dec 19 | 0 | -20 | 5 | 16 |
Quality Earnings: INZY is currently unprofitable.
Growing Profit Margin: INZY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INZY is unprofitable, and losses have increased over the past 5 years at a rate of 19.6% per year.
Accelerating Growth: Unable to compare INZY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INZY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: INZY has a negative Return on Equity (-116.56%), as it is currently unprofitable.